구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | CDX-3379 and cetuximab (CDX-3379 and cetuximab) Eli Lilly / Merck KGaA·Advanced Head and Neck Squamous Ce… 2 trials |
|---|---|
Overview Program | CDX-3379 and cetuximab |
Overview Company | Eli Lilly / Merck KGaA |
Overview Modality | ANTIBODY |
Overview Target | Advanced Head and Neck Squamous Cell Car |
Overview Indication | Advanced Head and Neck Squamous Cell Carcinoma |
Overview Phase | PHASE_2 |
Overview Status | DISCONTINUED |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Toxicology Major finding | Molecular and Clinical Activity of CDX-3379, an Anti-ErbB3 Monoclonal Antibody, in Head and Neck Squamous Cell Carcinoma Patients.. ErbB3 and its ligand neuregulin-1 (NRG1) are widely expressed in head and neck squamous cell carcinoma (HNSCC) and associated with tumor progression. A "window-of-opportunity" study (NCT02473731) was conducted to evaluate the pharmacodynamic effects of CDX-3379, an an… |
Clinical Safety signal | Molecular and Clinical Activity of CDX-3379, an Anti-ErbB3 Monoclonal Antibody, in Head and Neck Squamous Cell Carcinoma Patients.. ErbB3 and its ligand neuregulin-1 (NRG1) are widely expressed in head and neck squamous cell carcinoma (HNSCC) and associated with tumor progression. A "window-of-opportunity" study (NCT02473731) was conducted to evaluate the pharmacodynamic effects of CDX-3379, an an… |
Clinical Selected reported efficacy | ORR 7% |
Clinical Reported ORR | 7% |
Clinical Result source | ClinicalTrials.gov NCT03254927 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT03254927 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | CDX-3379 and cetuximab (CDX-3379 and cetuximab) Eli Lilly / Merck KGaA·Advanced Head and Neck Squamous Ce… 2 trials |
|---|---|
Overview Program | CDX-3379 and cetuximab |
Overview Company | Eli Lilly / Merck KGaA |
Overview Modality | ANTIBODY |
Overview Target | Advanced Head and Neck Squamous Cell Car |
Overview Indication | Advanced Head and Neck Squamous Cell Carcinoma |
Overview Phase | PHASE_2 |
Overview Status | DISCONTINUED |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Toxicology Major finding | Molecular and Clinical Activity of CDX-3379, an Anti-ErbB3 Monoclonal Antibody, in Head and Neck Squamous Cell Carcinoma Patients.. ErbB3 and its ligand neuregulin-1 (NRG1) are widely expressed in head and neck squamous cell carcinoma (HNSCC) and associated with tumor progression. A "window-of-opportunity" study (NCT02473731) was conducted to evaluate the pharmacodynamic effects of CDX-3379, an an… |
Clinical Safety signal | Molecular and Clinical Activity of CDX-3379, an Anti-ErbB3 Monoclonal Antibody, in Head and Neck Squamous Cell Carcinoma Patients.. ErbB3 and its ligand neuregulin-1 (NRG1) are widely expressed in head and neck squamous cell carcinoma (HNSCC) and associated with tumor progression. A "window-of-opportunity" study (NCT02473731) was conducted to evaluate the pharmacodynamic effects of CDX-3379, an an… |
Clinical Selected reported efficacy | ORR 7% |
Clinical Reported ORR | 7% |
Clinical Result source | ClinicalTrials.gov NCT03254927 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT03254927 |
추천 비교
추천 비교